252 related articles for article (PubMed ID: 15655565)
21. Microvessel density in prostate carcinoma.
Bono AV; Celato N; Cova V; Salvadore M; Chinetti S; Novario R
Prostate Cancer Prostatic Dis; 2002; 5(2):123-7. PubMed ID: 12497001
[TBL] [Abstract][Full Text] [Related]
22. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
[TBL] [Abstract][Full Text] [Related]
23. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
24. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
25. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer.
Wang W; Bergh A; Damber JE
Clin Cancer Res; 2005 May; 11(9):3250-6. PubMed ID: 15867220
[TBL] [Abstract][Full Text] [Related]
26. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
27. Independent prognostic importance of microvessel density in clinically localized prostate cancer.
Halvorsen OJ; Haukaas S; Høisaeter PA; Akslen LA
Anticancer Res; 2000; 20(5C):3791-9. PubMed ID: 11268456
[TBL] [Abstract][Full Text] [Related]
28. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
Jones TD; Koch MO; Lin H; Cheng L
BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440
[TBL] [Abstract][Full Text] [Related]
29. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy.
Bauer JJ; Connelly RR; Sesterhenn IA; Bettencourt MC; McLeod DG; Srivastava S; Moul JW
Cancer; 1997 Mar; 79(5):952-62. PubMed ID: 9041158
[TBL] [Abstract][Full Text] [Related]
30. Cancer progression after anterograde radical prostatectomy for pathologic Gleason score 8 to 10 and influence of concomitant variables.
Serni S; Masieri L; Minervini A; Lapini A; Nesi G; Carini M
Urology; 2006 Feb; 67(2):373-8. PubMed ID: 16461088
[TBL] [Abstract][Full Text] [Related]
31. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
32. Expression of proto-oncogene c-kit in high risk prostate cancer.
Di Lorenzo G; Autorino R; D'Armiento FP; Mignogna C; De Laurentiis M; De Sio M; D'Armiento M; Damiano R; Vecchio G; De Placido S
Eur J Surg Oncol; 2004 Nov; 30(9):987-92. PubMed ID: 15498646
[TBL] [Abstract][Full Text] [Related]
33. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer.
Merrill MM; Lane BR; Reuther AM; Zhou M; Magi-Galluzzi C; Klein EA
Urology; 2007 Aug; 70(2):294-8. PubMed ID: 17826492
[TBL] [Abstract][Full Text] [Related]
34. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204
[TBL] [Abstract][Full Text] [Related]
35. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?
Jones TD; Koch MO; Bunde PJ; Cheng L
BJU Int; 2006 Mar; 97(3):480-4. PubMed ID: 16469012
[TBL] [Abstract][Full Text] [Related]
36. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
[TBL] [Abstract][Full Text] [Related]
37. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
[TBL] [Abstract][Full Text] [Related]
39. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
[TBL] [Abstract][Full Text] [Related]
40. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
